Jetty Overbeek

Head of R&D

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jetty Overbeek is the Head of R&D at the Pharmo Institute in the Netherlands. His research primarily focuses on the epidemiology and clinical outcomes of COVID-19, diabetes management, and the quality of healthcare data. Recent articles include studies on the rates of SARS-CoV-2 breakthrough infections, treatment adherence in diabetes patients, and the impact of COVID-19 vaccination on menstrual disorders. Overbeek's work emphasizes the importance of improving healthcare through real-world data and clinical guidelines.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (16)

Marie Linder

Karolinska Institutet

SWEDEN

Jetty Overbeek

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

General practitioner consultation for postmenopausal bleeding after COVID‐19 vaccination—a self‐controlled cohort study

Rates of SARS-CoV-2 Breakthrough Infection or Severe COVID-19 and Associated Risk Factors After Primary and Booster Vaccination Against COVID-19 in the Netherlands

Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study

Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study

The patient journey of head neck cancer from primary care to diagnosis – A retrospective cohort study in the Netherlands

Type 2 Diabetes, the Epidemic: Trends in Prevalence and Incidence, 2004-2020

Improving Diagnosis and Care for Patients With Sarcoma: Do Real-World General Practitioners Data and Prospective Data Collections Have a Place Next to Clinical Trials?

GP consultations for menstrual disorders after COVID-19 vaccination – A self-controlled cohort study based on routine healthcare data from the Netherlands

Impact of implementing Dutch versus European guideline risk factor targets in older patients with ischaemic heart disease

The Impact of the COVID-19 Pandemic in The Netherlands on Primary Healthcare Use and Clinical Outcomes in Persons with Type 2 Diabetes

Completeness and Representativeness of the PHARMO General Practitioner (GP) Data: A Comparison with National Statistics.

Completeness and Representativeness of the PHARMO General Practitioner (GP) Data: A Comparison with National Statistics

Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries

Effectiveness of COVID-19 Vaccines in Adults with Diabetes Mellitus: A Systematic Review

Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time

The DIAbetes MANagement and Treatment (DIAMANT) Cohort.

Real-world data of HER2-low metastatic breast cancer: A population based cohort study.

Incidence of malignancies in patients with multiple sclerosis versus a healthy matched cohort: A population-based cohort study in the Netherlands using the PHARMO Database Network.

Use of intravenous iron and risk of anaphylaxis: A multinational observational post‐authorisation safety study in Europe

The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands.

Collaborators (16)

Marie Linder

Lia Gutierrez

J. Bradley Layton

Sarah E. R. Bailey

Carlos E. Durán

Meritxell Pallejà

Ron Herings

Winette van der Graaf

Antje Timmer

Tim Olde Hartman

Jonas Reinold

Leonard Wee

Agnes Kant

Felipe Villalobos Martínez

Patrick Blin

Joan Fortuny

Make your next move.